Device Trial Radar · NCT04793360
Molecular Assessment and Profiling of Liver Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
May 26, 2021
Primary completion
Dec 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- CareDxNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 11, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this protocol is to conduct longitudinal and prospective studies of liver transplant recipients, using a multimodality approach, akin to that used in kidney transplantation. The primary aim will compare the clinical outcomes of LiverCare post-transplant surveillance in liver transplant with standard of care consisting of liver function tests, DSA measurements, drug level monitoring, and 'for cause' biopsy. The protocol will assess the correlation between clinical events (e.g. rejection, recurrent disease, biliary obstruction), dd-cfDNA levels, gene expression profiling, ability to assess microchimerism, develop predictive analytics, infectious disease diagnoses and finally examine graft histology.
Conditions
- Liver Transplantation
- Biomarkers
Interventions
LiverCareDevice
The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To correlate the results of LiverCare with clinically significant events impacting post-transplant clinical outcomes, histological findings, and the development of de novo Donor Specific Antibody (DSA)Time frame: 2 years of accrual and 3 years follow up
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Keck Medical Center of USC
Los Angeles, California
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Tampa General Hospital
Tampa, Florida
23 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.